Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics


Cardiff Oncology, Inc. (CRDF): $2.01

0.08 (+4.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRDF to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRDF POWR Grades

  • CRDF scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.2% of US stocks.
  • The strongest trend for CRDF is in Quality, which has been heading down over the past 177 days.
  • CRDF's current lowest rank is in the Momentum metric (where it is better than 1.11% of US stocks).

CRDF Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CRDF is 0 -- better than merely 7.8% of US stocks.
  • CRDF's price/sales ratio is 229.67; that's higher than the P/S ratio of 98.32% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.08 for CARDIFF ONCOLOGY INC; that's greater than it is for only 7.87% of US stocks.
  • Stocks that are quantitatively similar to CRDF, based on their financial statements, market capitalization, and price volatility, are RXRX, CRBU, FULC, BCDA, and TGTX.
  • CRDF's SEC filings can be seen here. And to visit CARDIFF ONCOLOGY INC's official web site, go to www.cardiffoncology.com.

CRDF Valuation Summary

  • CRDF's EV/EBIT ratio is -1.6; this is 115.76% lower than that of the median Healthcare stock.
  • CRDF's price/sales ratio has moved down 2086.8 over the prior 190 months.

Below are key valuation metrics over time for CRDF.

Stock Date P/S P/B P/E EV/EBIT
CRDF 2023-01-30 200.0 0.7 -2.0 -1.6
CRDF 2023-01-27 198.7 0.7 -2.0 -1.6
CRDF 2023-01-26 197.7 0.7 -2.0 -1.6
CRDF 2023-01-25 196.4 0.7 -1.9 -1.5
CRDF 2023-01-24 195.9 0.7 -1.9 -1.5
CRDF 2023-01-23 203.3 0.7 -2.0 -1.6

CRDF Growth Metrics

    Its 2 year revenue growth rate is now at 3.07%.
  • Its 2 year price growth rate is now at 12.61%.
  • Its 2 year net income to common stockholders growth rate is now at -105.32%.
CRDF's revenue has moved down $94,336 over the prior 49 months.

The table below shows CRDF's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.391 -31.82 -39.473
2022-06-30 0.384 -29.799 -37.815
2022-03-31 0.361 -27.405 -34.129
2021-12-31 0.359 -23.04 -28.315
2021-09-30 0.345255 -20.77394 -25.47011
2021-06-30 0.395656 -18.83417 -23.0537

CRDF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRDF has a Quality Grade of D, ranking ahead of 16.71% of graded US stocks.
  • CRDF's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
  • OTIC, AVDL, and CORT are the stocks whose asset turnover ratios are most correlated with CRDF.

The table below shows CRDF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 1 -0.388
2021-03-31 0.004 1 -0.758
2020-12-31 0.007 1 17.949
2020-09-30 0.014 1 22.880
2020-06-30 0.015 1 50.452
2020-03-31 0.028 1 -56.954

CRDF Price Target

For more insight on analysts targets of CRDF, see our CRDF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.33 Average Broker Recommendation 1.5 (Moderate Buy)

CRDF Stock Price Chart Interactive Chart >

Price chart for CRDF

CRDF Price/Volume Stats

Current price $2.01 52-week high $3.56
Prev. close $1.93 52-week low $1.13
Day low $1.93 Volume 374,300
Day high $2.07 Avg. volume 283,117
50-day MA $1.52 Dividend yield N/A
200-day MA $1.80 Market Cap 89.80M

Cardiff Oncology, Inc. (CRDF) Company Bio


Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


CRDF Latest News Stream


Event/Time News Detail
Loading, please wait...

CRDF Latest Social Stream


Loading social stream, please wait...

View Full CRDF Social Stream

Latest CRDF News From Around the Web

Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.

Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer (CMO). Dr. Kabbinavar will oversee the clinical development program for the Company's investigational drug onvansertib and will report directly to Chief Executiv

Yahoo | February 2, 2023

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, which is taking place virtually from January 18 – 19, 2023.

Yahoo | January 10, 2023

Cardiff Oncology: Staying The Course (NASDAQ:CRDF)

Cardiff Oncology''s stock is down in recent months due to some strategic changes. Read more to see a full investment analysis of CRDF stock.

Seeking Alpha | December 14, 2022

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in fireside chats and 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference and the JMP Securities Hematology and Oncology Summit taking place on November 29 – December 1, 2022, and December 6 – 7, 2022, respectively.

Yahoo | November 21, 2022

Cardiff Oncology to Present at the Jefferies London Healthcare Conference

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies London Healthcare Conference, which is taking place in London, UK from November 15 – 17, 2022.

Yahoo | November 8, 2022

Read More 'CRDF' Stories Here

CRDF Price Returns

1-mo 38.62%
3-mo 58.27%
6-mo -33.44%
1-year -40.71%
3-year 9.84%
5-year -91.28%
YTD 43.57%
2022 -76.71%
2021 -66.59%
2020 1,350.81%
2019 -60.63%
2018 -85.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7315 seconds.